Mark Feinberg, MD, PhD, serves as the president and CEO of the International AIDS Vaccine Initiative (IAVI). In this role, Feinberg leads a global team dedicated to advancing vaccine development and other biomedical innovations that protect against HIV, TB, and other infectious diseases. Previously, Feinberg was chief public health and science officer at Merck Vaccines where he aided in the development and accessibility of a number of different vaccines. He also led many initiatives to address health issues in low-income countries, including the creation of the MSD-Wellcome Trust Hilleman Laboratories and the organization of a private-public partnership to advance the development of an Ebola vaccine. He also spent over 20 years researching HIV/AIDS and emerging diseases in both government and academia. Feinberg is a member of the Council on Foreign Relations and the Association of American physicians, as well as a fellow of the American College of Physicians. He received his bachelor’s degree from the University of Pennsylvania, and his MD and PhD from Stanford University.